Ann: Preliminary Final Report, page-65

Thanks @Taurean7 ...an interesting reflection.   I raised the issue of additional Executive resources with the CEO at the last AGM noting her (apparent) focus on Advandgen versus the need to provide some impetus on the two Mk elements of the Cellmid conglomerate. The response was that CDY were careful with Executive expenses as a similarly experienced Executive would not be within the current remuneration budget.
The Mk portfolio atm is largely resourced through partnership endeavours with CDY holding the IP and providing the MkAB for product development.  Clearly this will have to change as the Mk pre-clinical work migrates to Ph1 and beyond.  Alternatively, this may occur if CDY were to separate into independent entities which my instinct says is part of the longer term strategy as each entity matures.

In the interim I am confident the current executive are advancing the CDY conglomerate satisfactorily within budgetary and resource constraints.  These constraints may well loosen as the raising $$$ are put to good use.